Is VIVS or XFOR more undervalued in 2026?

CirclFi compares VivoSim Labs, Inc. (VIVS) and X4 Pharmaceuticals, Inc. (XFOR) using 13 institutional-grade valuation models. VIVS has a Quality of Company score of 4.5/10 while XFOR scores 5.1/10.

Which is a better buy — VIVS or XFOR?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do VIVS and XFOR valuations compare?

VIVS at $1.31 and XFOR at $4.31 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

VIVS vs XFOR Valuation Comparison 2026 — Intrinsic Value Analysis

VIVS

Biological Products, (No Diagnostic Substances)

VivoSim Labs, Inc.

Quality

4.5

out of 10

Value Trap

WARN

Price

$1.31

Last close

Models

10/13

Active

XFOR

Biological Products, (No Diagnostic Substances)

X4 Pharmaceuticals, Inc.

Quality

5.1

out of 10

Value Trap

WARN

Price

$4.31

Last close

Models

11/13

Active

Model-by-Model Comparison

Model	Type	VIVS Fair Value	VIVS Upside	XFOR Fair Value	XFOR Upside
Bayesian DCF	Intrinsic	$1.05	-19.7%	$2.12	-50.7%
Earnings Power Value	Intrinsic	$3.09	+114.7%	$3.32	-20.8%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for VIVS vs XFOR — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

VIVS vs XFOR — Which Stock Is More Undervalued?

XFOR scores higher with a 5.1/10 quality rating vs VIVS's 4.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing VivoSim Labs, Inc. (VIVS) and X4 Pharmaceuticals, Inc. (XFOR) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

VIVS currently trades at $1.31 with a QOC of 4.5/10, while XFOR trades at $4.31 with a QOC of 5.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).